Virtual Library

Start Your Search

D. Fanale

Author of

  • +

    Poster Display Session (ID 63)

    • Event: ELCC 2017
    • Type: Poster Display Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
    • +

      148P - Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: A pooled analysis (ID 406)

      12:30 - 13:00  |  Author(s): D. Fanale

      • Abstract

      Recent studies evaluated the potential role of EGFR mutation testing by using circulating tumor DNA (ctDNA) isolated from plasma of NSCLC patients, overall showing a lower sensitivity compared with the standard tissue genotyping. However, it’s less clear if the presence of extrathoracic (M1b) disease may enhance the ability to identify EGFR mutations in plasma. This pooled analysis aims to evaluate the association between metastatic site location and sensitivity of ctDNA analysis.

      Data from all published studies, that evaluated the sensitivity of plasma-based EGFR-mutation testing, stratified by metastatic site location (extrathoracic (M1b) vs intrathoracic (M1a)) were collected by searching in PubMed, Cochrane Library, American Society of Clinical Oncology, and World Conference of Lung Cancer, meeting proceedings. Pooled Odds ratio (OR) and 95% confidence intervals (95% CIs) were calculated for the ctDNA analysis sensitivity, according to the metastatic site location.

      A total of seven studies, with 1233 patients, were eligible. Pooled analysis showed that the sensitivity of EGFR-mutation testing by ctDNA was significantly higher in patients with extrathoracic disease (M1b) compared to patients with intrathoracic (M1a) disease (OR: 4.29; 95% CIs: 2.20 – 8.38).

      These data suggest that the location of metastatic sites significantly influences the diagnostic accuracy of ctDNA analysis. Particularly the ability to identify EGFR activating mutations in plasma of NSCLC patients is significantly higher in the presence of M1b vs M1a disease. These observations could influence the clinical management of EGFR-mutated patients.

      Clinical trial identification:

      Legal entity responsible for the study:
      Palermo University Hospital

      Palermo University Hospital

      All authors have declared no conflicts of interest.